HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

ezetimibe (Zetia)

structure given in first source

Also Known As:

Zetia; ezetimib; (1-(4-fluorophenyl)-(3R)-(3-(4-fluorophenyl)-(3S)-hydroxypropyl)-(4S)-(4-hydroxyphenyl)-2-azetidinone); Essex brand of ezetimibe; Ezetrol; MSD brand of ezetimibe; Merck brand of ezetimibe; SCH 58235; SCH-58235; SCH58235; Schering-Plough brand of ezetimibe

Networked: 827 relevant articles (121 outcomes, 287 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Azetines
    - Azetidines: 2
      - ezetimibe: 827

Experts

1.	Wachtell, Kristian: 29 articles (12/2015 - 04/2007)
2.	Gerdts, Eva: 28 articles (11/2015 - 04/2007)
3.	Tershakovec, Andrew M: 27 articles (10/2015 - 10/2006)
4.	Ray, Simon: 24 articles (12/2015 - 04/2007)
5.	Boman, Kurt: 23 articles (12/2015 - 04/2007)
6.	Rossebø, Anne B: 21 articles (11/2015 - 04/2007)
7.	Ballantyne, Christie M: 18 articles (11/2015 - 05/2003)
8.	Pedersen, Terje R: 17 articles (11/2015 - 04/2007)
9.	Cramariuc, Dana: 17 articles (11/2015 - 02/2008)
10.	Egstrup, Kenneth: 17 articles (02/2015 - 04/2007)

Related Diseases

1.	Hypercholesterolemia 08/01/2004 - "Coadministration of ezetimibe + statin offers a well-tolerated, highly efficacious new treatment strategy for patients with hypercholesterolemia." 01/01/2012 - "Ezetimibe added to ongoing statin therapy resulted in significantly greater lipid-lowering compared with doubling the dose of statin in Taiwanese patients with hypercholesterolemia. " 01/01/2009 - "Furthermore, ezetimibe add-on therapy improved vascular endothelial function in high-risk patients with hypercholesterolemia. " 05/01/2003 - "These studies establish ezetimibe as an effective lipid-lowering agent, which will likely be useful in the management of a broad range of patients with hypercholesterolemia. " 01/01/2011 - "Therefore, the objective in this study was to clarify the vascular protective effects of ezetimibe in patients with hypercholesterolemia. "
2.	Dyslipidemias (Dyslipidemia) 11/01/2008 - "Ezetimibe has proved effective for the treatment of dyslipidemia in these patients. " 06/01/2010 - "In the present study, we evaluated the efficacy of 6 months of ezetimibe treatment for NASH patients with dyslipidemia for the comparison of improvement of the clinical parameters and histological alterations. " 06/01/2015 - "Eight patients with dyslipidemia enrolled in this study completed blood and bile sampling before and at 3 months after ezetimibe treatment (10 mg/day), and the samples are analyzed. " 02/18/2015 - "In vitro studies using NPC1L1-overexpressing intestinal cells and in vivo studies with Npc1l1-knockout mice revealed that intestinal VK absorption is NPC1L1-dependent and inhibited by ezetimibe, an NPC1L1-selective inhibitor clinically used for dyslipidemia. " 01/01/2012 - "The aim of the present study was to test efficacy and safety of statin plus ezetimibe combination in the treatment of severe dyslipidemia in patients coming to an ordinary lipid and diabetology department. "
3.	Hyperlipidemias (Hyperlipidemia) 10/01/2010 - "Ezetimibe is a well-tolerated and effective (in terms of achieving LDL-C targets) option inpatients with hyperlipidemia with or without diabetes. " 09/01/2013 - "Therefore, ezetimibe ameliorates postprandial hyperlipidemia. " 01/01/2013 - "Ezetimibe is a comparatively new drug for the treatment of hyperlipidemia having lesser adverse effect as compared to statin. " 01/01/2012 - "[Statin-ezetimibe combination in hyperlipidemia treatment]." 08/01/2011 - "Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction."
4.	Atherosclerosis 01/01/2011 - "Moreover, known and proposed mechanisms of how ezetimibe could improve ROS-induced pro-atherosclerotic conditions in vasculature are discussed; these effects may help to explain the mechanisms by which ezetimibe may protect vascular from atherosclerosis." 12/01/2015 - "We hypothesize these trials could demonstrate that (1) very aggressive LDL-C lowering with PCSK-9 mAbs added to background statin therapy will induce extensive atherosclerosis stabilization and regression in the large majority of treated patients, and (2) continued maintenance therapy with high intensity statin therapy (with or without ezetimibe) should then inhibit new plaque formation, with a long-term prevention of CVD events. " 01/01/2013 - " trials resulted in controversial outcomes with some studies reporting atherosclerosis regression and reductions in CVD events following ezetimibe therapy in combination with a statin while others reported negative results. " 01/01/2011 - "However, further studies should elucidate the mechanism of the anti-atherosclerotic effects induced by ezetimibe; for instance, whether or not it directly affects atherogenesis independently from its lipid-lowering effects." 01/01/2012 - " These observations may provide some insights into how ezetimibe prevents atherosclerosis."
5.	Insulin Resistance 03/28/2012 - "Aims/Introduction: Several experimental studies have shown that ezetimibe improves steatosis and insulin resistance in the liver. " 05/01/2015 - "However, the effect of ezetimibe on insulin resistance remains unclear. " 05/01/2011 - "SHP silencing mainly in the liver worsened insulin resistance, and ezetimibe protected against insulin resistance induced by down-regulation of SHP. " 11/01/2010 - "It has been shown that ezetimibe-treated mice are protected from diet-induced insulin resistance. " 10/01/2010 - "Ezetimibe also seems to improve renal function, insulin resistance and inflammatory markers. "

Related Drugs and Biologics

1.	Simvastatin (Zocor)
2.	atorvastatin (Lipitor)
3.	Cholesterol
4.	LDL Cholesterol
5.	rosuvastatin (Crestor)
6.	simvastatin drug combination ezetimibe (Vytorin)
7.	Lipoproteins (Lipoprotein)
8.	Glucose (Dextrose)
9.	Niacin (Nicotinic Acid)
10.	Fenofibrate (CiL)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Transplantation (Transplant Recipients)
3.	Homologous Transplantation (Allograft)
4.	Continuous Ambulatory Peritoneal Dialysis (CAPD)
5.	Stents